This article features deals sourced directly by Gizmodo and produced independently of the editorial team. We may earn a commission when you buy through links on the site. Reading time 2 minutes Put on ...

This article features deals sourced directly by Gizmodo and produced independently of the editorial team. We may earn a commission when you buy through links on the site. Reading time 2 minutes If you ...

Critical Role Campaign 4 has finally released its official intro—and it’s a little different than anything we’ve seen before. This time, Critical Role Campaign 4 has opted for a very vibes-forward ...

We recently published 10 Stocks Losing Big. ESSA Pharma Inc. (NASDAQ:EPIX) is one of the worst performers of Tuesday. ESSA Pharma nosedived by 66.39 percent on Tuesday to end at $0.2631 apiece as ...

Looking for a premium Garmin smartwatch without paying full price? The Garmin Epix Pro (Gen 2) Sapphire Edition is now on sale for just $675, down from its usual $999 price—a solid 32% discount. This ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Pharma Inc. (NASDAQ: EPIX) to XenoTherapeutics, Inc. is fair to ESSA shareholders.

Jay primarily writes news and deals posts for Android Police. Before joining AP, he spent the past several years yammering on about the crazy world of Android for various tech outlets. Besides ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) ...

Tristan Jurkovich began his career as a journalist in 2011. His childhood love of video games and writing fuel his passion for archiving this great medium’s history. He dabbles in every genre, but ...

Get up to speed on the weird world of AI in just six editions of our new free newsletter. It feels as though AI is moving a million miles a minute. Every week, it seems, there are product launches, ...

This has been a big week for Garmin, with the announcement of the Fenix 8 and Enduro 3 families, but it’s also a time to give a nod to a range that may be coming to an end for now, Garmin Epix.

ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to ...